Selskabsmeddelelse

Communiqué from the Annual General Meeting of Xintela AB (publ)

Today, Friday 12 May 2023, the Annual General Meeting was held in Xintela AB (publ). The following main decisions were made. The decisions were taken unanimously.

Profit allocation and decision on discharge from liability
The meeting decided, in accordance with the board's proposal, that no dividend is to be paid for the financial year 2022 and that the company's results shall be carried forward.

The meeting granted the board members and the CEO discharge from liability for the financial year 2022.

Election and remuneration of the board and auditor
The meeting decided that the board shall consist of five board members without deputies. Gregory Batcheller, Lars Hedbys, Maarten de Chateau, Hans-Joachim Simons and Thomas Eldered were re-elected as board members. Gregory Batcheller was re-elected chairman of the board.

The meeting further decided that remuneration to the members of the board shall amount to a total of SEK 900,000, whereby SEK 300,000 shall be paid to the chairman of the board and SEK 150,000 shall be paid to other board members.

The meeting also decided to re-elect Öhrlings PricewaterhouseCoopers AB as auditor and that the auditor's fee should be paid according to approved invoices.

Issue authorizations
The meeting decided, in accordance with the board's proposal, to authorize the board to, within the limits of the articles of association, only with preferential rights for the company's shareholders, decide on a new issue of shares or the issue of convertibles or warrants.

The meeting further decided, in accordance with the board's proposal, to authorize the board to, deviating from the shareholders' pre-emptive rights, decide on a new issue of shares or the issue of convertibles or warrants. Decisions supported by the authorization may not result in the number of shares in the company being increased by more than a total of 20 percent of the number of shares outstanding at the time of the meeting. The purpose of the authorization, and the reason for the deviation from the shareholders' preferential right, is to enable the company to widen the ownership circle, acquire or enable the acquisition of working capital, increase the liquidity of the share, carry out business acquisitions or acquire or enable the acquisition of capital for business acquisitions.

Introduction of incentive programs
The meeting decided in accordance with the board's proposal to introduce a long-term incentive program for senior executives, employees and consultants in Xintela AB (publ) by issuing warrants.

The meeting further decided, in accordance with Flerie Invest AB's proposal, to introduce a long-term incentive program for board members in Xintela AB (publ) by issuing warrants.

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB.